These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25945018)

  • 1. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
    Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
    World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
    Sakata Y; Tominaga K; Kato M; Takeda H; Shimoyama Y; Takeuchi T; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Fujimoto K; Kusano M; Arakawa T;
    BMC Gastroenterol; 2014 Jul; 14():116. PubMed ID: 24990161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.
    Tominaga K; Kato M; Takeda H; Shimoyama Y; Umegaki E; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Kusano M; Fujimoto K; Arakawa T;
    J Gastroenterol; 2014 Oct; 49(10):1392-405. PubMed ID: 24535455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment].
    Yang XL; Liu XH; Ke MY; Song ZQ; Yuan YZ; Luo JY; Hou XH
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2404-7. PubMed ID: 20137694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
    Kinoshita Y; Ashida K; Hongo M;
    Aliment Pharmacol Ther; 2011 Jan; 33(2):213-24. PubMed ID: 21083596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
    Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
    Liu XH; Ke MY; Song ZQ; Luo JY; Yuan YZ; Hou XH; Zhu YL; Sun J; Zha H
    Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):818-21. PubMed ID: 16316559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M; Manabe N; Haruma K
    Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of a modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease to distinguish functional dyspepsia from non-erosive reflux disease.
    Kusano M; Hosaka H; Kawada A; Kuribayashi S; Shimoyama Y; Kawamura O; Moki F
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1187-91. PubMed ID: 22414314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
    Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
    J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment prediction of symptom response to proton pump inhibitor therapy.
    Nagahara A; Miwa H; Asaoka D; Shimada Y; Sasaki H; Matsumoto K; Osada T; Hojo M; Watanabe S
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():25-30. PubMed ID: 25827800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
    Kobeissy AA; Hashash JG; Jamali FR; Skoury AM; Haddad R; El-Samad S; Ladki R; Aswad R; Soweid AM
    World J Gastroenterol; 2012 May; 18(19):2390-5. PubMed ID: 22654431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan.
    Funaki Y; Kaneko H; Kawamura Y; Yoshimine T; Tamura Y; Izawa S; Ebi M; Ogasawara N; Sasaki M; Kasugai K
    Digestion; 2017; 96(1):39-45. PubMed ID: 28641289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
    Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
    World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.
    Hussain S; Kierkus J; Hu P; Hoffman D; Lekich R; Sloan S; Treem W
    J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):226-36. PubMed ID: 24121146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
    Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
    J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole].
    Fan YH; Lü B; Zhan LX; Zhang L
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):475-7. PubMed ID: 17663823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.